| Loading hydrophilic drug in solid lipid media as nanoparticles: statistical modeling of entrapment efficiency and particle size M Ghadiri, S Fatemi, A Vatanara, D Doroud, AR Najafabadi, M Darabi, ... International journal of pharmaceutics 424 (1-2), 128-137, 2012 | 163 | 2012 |
| Helicobacter pylori antibiotic resistance in Iran M Mohammadi, D Doroud, N Mohajerani, S Massarrat World journal of gastroenterology: WJG 11 (38), 6009, 2005 | 96 | 2005 |
| Delivery of a cocktail DNA vaccine encoding cysteine proteinases type I, II and III with solid lipid nanoparticles potentiate protective immunity against Leishmania major infection D Doroud, F Zahedifard, A Vatanara, AR Najafabadi, Y Taslimi, ... Journal of controlled release 153 (2), 154-162, 2011 | 92 | 2011 |
| Development of Novel Prime-Boost Strategies Based on a Tri-Gene Fusion Recombinant L. tarentolae Vaccine against Experimental Murine Visceral Leishmaniasis N Saljoughian, T Taheri, F Zahedifard, Y Taslimi, F Doustdari, ... PLoS neglected tropical diseases 7 (4), e2174, 2013 | 75 | 2013 |
| Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model M Heidari‐Kharaji, T Taheri, D Doroud, S Habibzadeh, A Badirzadeh, ... Parasite immunology 38 (10), 599-608, 2016 | 74 | 2016 |
| Cationic solid lipid nanoparticles loaded by cystein proteinase genes as a novel anti-leishmaniasis DNA vaccine delivery system: characterization and in vitro evaluations D Doroud, A Vatanara, F Zahedifard, E Gholami, R Vahabpour, ... Journal of Pharmacy & Pharmaceutical Sciences 13 (3), 320-335, 2010 | 74 | 2010 |
| Cationic solid–lipid nanoparticles are as efficient as electroporation in DNA vaccination against visceral leishmaniasis in mice N Saljoughian, F Zahedifard, D Doroud, F Doustdari, M Vasei, ... Parasite Immunology 35 (12), 397-408, 2013 | 60 | 2013 |
| Drug Targeting to Macrophages With Solid Lipid Nanoparticles Harboring Paromomycin: an In Vitro Evaluation Against L. major and L. tropica MH Kharaji, D Doroud, T Taheri, S Rafati Aaps Pharmscitech 17, 1110-1119, 2016 | 52 | 2016 |
| Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials M Eugenia-Toledo-Romaní, L Verdecia-Sánchez, M Rodríguez-González, ... Vaccine 40 (31), 4220-4230, 2022 | 50* | 2022 |
| Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind … ME Toledo-Romaní, M García-Carmenate, C Valenzuela-Silva, ... The Lancet Regional Health–Americas 18, 2023 | 47 | 2023 |
| Solid lipid nanoparticle loaded with paromomycin: in vivo efficacy against Leishmania tropica infection in BALB/c mice model M Heidari-Kharaji, T Taheri, D Doroud, S Habibzadeh, S Rafati Applied microbiology and biotechnology 100, 7051-7060, 2016 | 45 | 2016 |
| Development and physicochemical, toxicity and immunogenicity assessments of recombinant hepatitis B surface antigen (rHBsAg) entrapped in chitosan and mannosylated chitosan … M Mehrabi, NM Dounighi, SM Rezayat Sorkhabadi, D Doroud, A Amani, ... Artificial cells, nanomedicine, and biotechnology 46 (sup1), 230-240, 2018 | 44 | 2018 |
| Paromomycin loaded solid lipid nanoparticles: characterization of production parameters M Ghadiri, A Vatanara, D Doroud, A Roholamini Najafabadi Biotechnology and bioprocess engineering 16, 617-623, 2011 | 43 | 2011 |
| Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice D Doroud, F Zahedifard, A Vatanara, AR Najafabadi, S Rafati Parasite Immunology 33 (6), 335-348, 2011 | 42 | 2011 |
| Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis M Shahbazi, F Zahedifard, N Saljoughian, D Doroud, S Jamshidi, ... Veterinary parasitology 212 (3-4), 130-139, 2015 | 32 | 2015 |
| Leishmaniasis: focus on the design of nanoparticulate vaccine delivery systems D Doroud, S Rafati Expert review of vaccines 11 (1), 69-86, 2012 | 31 | 2012 |
| Clarithromycin resistance in Iranian H. pylori strains before introduction of clarithromycin. M Mohammadi, D Doroud, S Massarrat, MJ Farahvash Helicobacter 8 (1), 2003 | 29 | 2003 |
| Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein … R Puga-Gómez, Y Ricardo-Delgado, C Rojas-Iriarte, ... International Journal of Infectious Diseases 126, 164-173, 2023 | 24 | 2023 |
| C-Terminal Domain Deletion Enhances the Protective Activity of cpa/cpb Loaded Solid Lipid Nanoparticles against Leishmania major in BALB/c Mice D Doroud, F Zahedifard, A Vatanara, Y Taslimi, R Vahabpour, ... PLoS neglected tropical diseases 5 (7), e1236, 2011 | 24 | 2011 |
| Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults ME Toledo-Romani, M García-Carmenate, L Verdecia-Sánchez, ... Med 3 (11), 760-773. e5, 2022 | 22 | 2022 |
Sima RafatiPasteur Institute of Iran在 pasteur.ac.ir 的电子邮件经过验证
